{
    "root": "2124d0de-8f96-6f0d-6c42-7296def2661f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ProHance",
    "value": "20250314",
    "ingredients": [
        {
            "name": "gadoteridol",
            "code": "0199MV609F"
        },
        {
            "name": "calteridol calcium",
            "code": "RPH56VWA1A"
        },
        {
            "name": "tromethamine",
            "code": "023C2WHX2V"
        }
    ],
    "indications": "prohance gadolinium-based contrast agent indicated magnetic resonance imaging ( mri ) visualize : lesions disrupted blood brain barrier and/or abnormal vascularity brain ( intracranial lesions ) , spine associated tissues adults pediatric patients , including term neonates ( 1.1 ) lesions head neck adults ( 1.2 )",
    "contraindications": "recommended dose adult pediatric patients 0.2 ml/kg ( 0.1 mmol/kg ) body weight administered rapid intravenous infusion bolus ( 2.1 ) follow injection saline flush least 5 ml normal saline ( 2.1 )",
    "warningsAndPrecautions": "supplied prohance supplied sterile , nonpyrogenic , colorless slightly yellow solution containing 279.3 mg/ml ( 0.5 mmol/ml ) gadoteridol single-dose rubber stoppered vials prefilled syringes ; prohance available boxes : five 5 ml fills single dose 15 ml vials ( ndc 0270-1111-04 ) five 10 ml fills single dose 30 ml vials ( ndc 0270-1111-01 ) five 15 ml fills single dose 30 ml vials ( ndc 0270-1111-02 ) five 20 ml fills single dose 30 ml vials ( ndc 0270-1111-03 ) storage handling store 25\u00b0c ( 77\u00b0 f ) . excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect light . freeze . freezing occur vial , prohance brought room temperature . allowed stand room temperature minimum 60 minutes , prohance return clear , colorless slightly yellow solution . , examine product assure solids redissolved container closure damaged . solids persist , discard vial .",
    "adverseReactions": "prohance contraindicated patients known allergic hypersensitivity prohance [ ( 5.3 ) ] .",
    "indications_original": "ProHance\nis a gadolinium-based contrast agent indicated for magnetic resonance\nimaging (MRI) to visualize: lesions with disrupted blood brain barrier and/or abnormal\nvascularity in the brain (intracranial lesions), spine and associated\ntissues in adults and pediatric patients, including term neonates\u00a0( 1.1 ) lesions in the head and neck in adults ( 1.2 )",
    "contraindications_original": "Recommended dose in adult and pediatric patients is 0.2\nmL/kg (0.1 mmol/kg) body weight administered as rapid intravenous\ninfusion or bolus ( 2.1 ) Follow injection with a saline flush of at least 5 mL normal\nsaline ( 2.1 )",
    "warningsAndPrecautions_original": "How Supplied\n                     ProHance is supplied as a sterile, nonpyrogenic, and\ncolorless to slightly yellow solution containing 279.3 mg/mL (0.5\nmmol/mL) of gadoteridol in single-dose rubber stoppered vials or prefilled\nsyringes; ProHance is available in boxes of:\n                  Five 5 mL fills\nin single dose 15 mL vials (NDC 0270-1111-04)Five 10 mL\nfills in single dose 30 mL vials (NDC 0270-1111-01)Five\n15 mL fills in single dose 30 mL vials (NDC 0270-1111-02)Five 20 mL fills in single dose 30 mL vials (NDC 0270-1111-03)\n                  \n                     Storage and Handling\n                     Store at 25\u00b0C (77\u00b0 F).\nExcursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled\nRoom Temperature]. Protect from light. DO NOT FREEZE. Should freezing\noccur in the vial, ProHance should be brought to room temperature\nbefore use. If allowed to stand at room temperature for a minimum\nof 60 minutes, ProHance should return to a clear, colorless to slightly\nyellow solution. Before use, examine the product to assure that all\nsolids are redissolved and that the container and closure have not\nbeen damaged. Should solids persist, discard vial.",
    "adverseReactions_original": "ProHance is contraindicated\nin patients with known allergic or hypersensitivity reactions to ProHance [see Warnings and Precautions (5.3)]."
}